ABSTRACT Sera from tumor-bearing mice immunoprecipitated a 86,000-dalton glycoprotein from extracts of NIH 
Recent studies have demonstrated that transforming genes of cellular origin can be detected by the biological activity of cellular DNAs in transfection assays. DNA fragments of normal cells have a low transforming activity which is thought to represent activation of potential transforming genes as a consequence of DNA rearrangements during donor DNA integration (1) . DNAs of various transformed cells induce transformation with high efficiencies indicating that, in some transformed cells, carcinogenesis has involved DNA alterations leading to activation of dominant cellular transforming genes which can then be efficiently transmitted by transfection. Neoplastic cells in which activation of transmissible transforming genes has been detected include chemically transformed mouse fibroblasts (2) , chicken bursal lymphomas and a nephroblastoma (3) , human, rabbit, and mouse bladder carcinomas (4, 5) , a mouse lung carcinoma (5), mouse and rat neuroblastomas and gliomas (5), a human colon carcinoma (6), a human promyelocytic leukemia (6) , human and mouse mammary carcinomas (7) , and human and mouse B-and T-lymphocyte neoplasms (8) .
Restriction endonuclease analysis of the transforming genes of mammary carcinomas indicated that the same or closely related transforming genes were activated in a human mammary carcinoma cell line and in six independent mouse mammary carcinomas induced by either viral or chemical carcinogens (7) . Similar analysis of the transforming genes ofhuman and mouse lymphoid neoplasms indicates that specific transforming genes are activated in neoplasms representative of specific stages of B-and T-lymphocyte differentiation (8) . However, the transforming genes activated in mammary carcinomas and lymphoid neoplasms are distinct from each other and from transforming genes activated in human bladder carcinomas (4) , chemically transformed mouse fibroblasts (9) , and NIH cells transformed by normal chicken DNA (1) . In addition, analysis of repetitive DNA sequences associated with the transforming genes of a human bladder carcinoma, a human colon carcinoma, and a human promyelocytic leukemia indicates that different transforming genes are activated in these three different neoplasms (6) . These results thus indicate that specific transforming genes are activated in neoplasms of specific types of differentiated cells.
Here we report the identification of an antigen associated with the transforming genes of human and mouse mammary carcinomas. These findings further support the involvement of a common transformation pathway in a human mammary carcinoma cell line, independent virus-induced mouse mammary carcinomas, and a chemically induced mouse mammary carcinoma. The identification of this antigen may provide an approach to the study of the biochemical events that mediate transformation in this system.
MATERIALS AND METHODS
Tumors and Cell Lines. The human mammary carcinoma cell line MCF-7 (10) was provided by L. B. Chen (Sidney Farber Cancer Institute). Primary mouse mammary tumor virus (MMTV)-induced mammary carcinomas were obtained from C3H/He SFCI Nu/+ retired breeder females. NIH cells transformed by human and mouse mammary carcinoma DNAs (7), human bladder carcinoma DNAs (4), and Rous sarcoma virus DNA (11) were as described. NIH cells transformed by normal human DNA were isolated by transfection with DNA fragments of normal human embryo lung fibroblasts (IMR 90 cells) (12) as described (1) .
Preparation of Antisera. BALB/c mice (8-10 weeks old) were injected intraperitoneally at 3-to 4-day intervals with 5-10 x 105 NIH cells transformed by mammary carcinoma DNAs. As reported (7), these mice developed multiple focal tumors throughout the peritoneal cavity within 10-14 days. Sera were obtained from tumor-bearing mice 14-21 days after initial inoculation. Control sera were obtained from BALB/c mice injected in parallel with NIH 3T3 cells at 16 days after the initial injection; none ofthese mice developed tumors. Additional control sera were obtained from BALB/c mice bearing tumors induced by NIH cells transformed by human bladder carcinoma DNA or by normal human DNA. Sera were also obtained from normal primaparous C3H mice and from C3H mice bearing MMTV-induced mammary carcinomas.
Immunoprecipitation Assays. Cells were plated at a density of [3] [4] [5] (13) .
After lysis, the culture dishes were scraped with a rubber policeman and the contents were centrifuged in an Eppendorf microcentrifuge for 15 min at 12,000 X g at 40C. Lysates were then incubated with 50 Al of either a 50% (wt/vol) suspension of protein A-Sepharose beads (Pharmacia) or a 10% (wt/vol) suspension offormaldehyde-fixed Staphylococcus aureus (Pansorbin, Calbiochem-Behring). After incubation for 10 min at 40C with agitation; the lysates were centrifuged and this step was repeated. Lysates were then agitated for 30 min at 4°C with 5 Al of control serum from BALB/c mice that had been inoculated with NIH 3T3 cells and for an additional 30 min after addition of5 ,A ofrabbit anti-mouse immunoglobulin antiserum (Calbiochem-Behring) and 50 ,ul of either a 50% suspension of protein A-Sepharose beads or a 10% suspension of formaldehyde-fixed S. aureus.
These lysates were centrifuged, divided in half, and incubated with 10 ,ul of serum from either control or tumor-bearing mice for 5-6 hr at 4°C. They were then incubated for an additional hour with 10 lu of rabbit anti-mouse immunoglobulin antiserum and 100 ,l of a 50% suspension of protein A-Sepharose beads. Bead immunocomplexes were recovered by centrifugation, washed four times with 1 ml of RIPA buffer, resuspended in 30 ,A of sample buffer [62.5 mM Tris-HCI, pH 6.8/2% NaDodSOJ2 mM EDTA/10% (vol/vol) glycerol/5% (wt/vol) 2-mercaptoethanol/0.01% bromphenol blue], and heated for 5 min at 100°C. Samples were analyzed by electrophoresis in NaDodSO4polyacrylamide gels as described by Laemmli (14) In addition to gp86, the experiment presented in Fig. 2 (Fig. 4) . Con (Fig. 6) 
